Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL-36 bempegaldesleukin + pembrolizumab vs pembrolizumab in first-line PD-L1+ metastatic/recurrent HNSCC
jRCT2031220385Phase 3Active, not recruiting
- Sponsor
- Nektar Therapeutics
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing bempegaldesleukin + pembrolizumab with pembrolizumab monotherapy (2 arms). Primary endpoints: Overall survival and Objective response rate. Started Oct 2022; status: active, not recruiting.
02
Drugs
bempegaldesleukinpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2031220385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220385.